Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 103Lymphoma 68Lymphoma, Large B-Cell, Diffuse 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Sarcoma 33Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Leukemia 23Burkitt Lymphoma 22Neoplasms 19Lymphoma, Mantle-Cell 18Triple Negative Breast Neoplasms 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, B-Cell 14Lymphoma, Large-Cell, Anaplastic 12Carcinoma, Hepatocellular 12Breast Neoplasms, Male 11Neuroblastoma 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Inflammatory Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Peripheral 8Lymphoma, T-Cell 8Osteosarcoma 7Fallopian Tube Neoplasms 7Urinary Bladder Neoplasms 6Liposarcoma 6

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × Doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡